The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Subscribe To Our Newsletter & Stay Updated
